Maxim analyst Anthony Vendetti raised the firm's price target on SeaStar Medical to $8 from $6 and keeps a Buy rating on the shares. The company's Q1 revenue, gross margin, and gap loss per share were all above estimates, the analyst tells investors in a research note. Maxim is raising its 2026 and 2027 revenue estimates for SeaStar but also widening its loss per share outlook due to higher expected operating expense, the firm added.
